ClinicalTrials.gg

Program

BV100

A development code. Also written as “BV100 (300 mg)”, “BV100 with 50 mg polymyxin B plus ceftazidime/avibactam” and “BV100 with 50 mg polymyxin B plus cefiderocol”.

Its studies are mostly in Bacterial Infections · Pneumonia, Bacterial · Meningitis, Bacterial · Pneumonia, Ventilator-Associated · Renal Insufficiency, led by 2 companies.

Furthest: phase 3, since Jan 4, 202311 company-led studies, 3 open or runningNext primary completion: Dec 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BioVersys71 open or runningphase 2since Jan 4, 2023Oct 8, 2021Mar 2028phase 2 · NCT07431307
BioVersys SAS42 open or runningphase 3since Jan 7, 2026Nov 10, 2020Dec 30, 2027phase 3 · NCT07326540

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 10, 2020First study: phase 1 study in Healthy SubjectsNew to BioVersys SASBioVersys SAS · NCT04636983 · 54 enrolled · Germany
  2. Oct 8, 2021BioVersys's first study: phase 1 study in Renal InsufficiencyNew to BioVersysBioVersys · NCT05086107 · 48 enrolled · Hungary
  3. Oct 9, 2021Phase 1 study in Healthy VolunteersBioVersys SAS · NCT05087069 · 16 enrolled · Germany
  4. Sep 7, 20222 phase 1 studiesBioVersys · NCT05537090, NCT05537142
  5. Jan 4, 2023Phase 2 study in Pneumonia, Ventilator-AssociatedBioVersys · NCT05685615 · 39 enrolled · Georgia, Greece, Hungary
  6. Jan 5, 20232 phase 1 studies in Bacterial InfectionsBioVersys · NCT05684718, NCT05684705
  7. Jan 7, 2026Phase 3 study in Hospital Acquired Bacterial Pneumonia (HABP)Phase 3 reachedBioVersys SAS · NCT07326540 · 248 planned · Georgia
  8. Feb 17, 2026Phase 2 study in Meningitis, BacterialBioVersys · NCT07431307 · 120 planned
  9. Apr 28, 2026Phase 1 study in Healthy Adult ParticipantsBioVersys SAS · NCT07580586 · 16 planned · Austria

Ahead

  1. Dec 30, 2027Primary completion: phase 3 study in Hospital Acquired Bacterial Pneumonia (HABP)BioVersys SAS · NCT07326540
  2. Mar 2028Primary completion: phase 2 study in Meningitis, BacterialBioVersys · NCT07431307

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07580586Healthy Adult Participants · Austria1RecruitingBioVersys SASSep 30, 202616
NCT07431307Meningitis, Bacterial2Not yet recruitingBioVersysMar 2028120
NCT07326540Hospital Acquired Bacterial Pneumonia (HABP) · Georgia3RecruitingBioVersys SASDec 30, 2027248
NCT05684718Bacterial Infections · Hungary1CompletedBioVersysSep 30, 202316
NCT05684705Bacterial Infections · Austria1CompletedBioVersysOct 30, 202435
NCT05685615Pneumonia, Ventilator-Associated · Georgia, Greece, Hungary2CompletedBioVersysNov 1, 202439
NCT05537142Healthy Participants · Hungary1CompletedBioVersysJul 30, 202433
NCT05537090Healthy Volunteers · Hungary1CompletedBioVersysJul 31, 202316
NCT05087069Healthy Volunteers · Germany1CompletedBioVersys SASApr 8, 202216
NCT05086107Renal Insufficiency · Hungary1CompletedBioVersysMay 30, 202248
NCT04636983Healthy Subjects · Germany1CompletedBioVersys SASDec 12, 202154

How it is read

Names in the registry

  • “BV100”, 6 entries
  • “BV100 (300 mg)”, 3 entries
  • “BV100 with 50 mg polymyxin B plus ceftazidime/avibactam”, 1 entry
  • “BV100 with 50 mg polymyxin B plus cefiderocol”, 1 entry
  • “BV100 plus Polymyxin B”, 1 entry

Codes read as this program: BV100.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.